This article needs additional citations for verification .(October 2022) |
Company type | Private |
---|---|
Industry | Pharmaceuticals |
Founded | 1929 |
Headquarters | Barcelona, Spain |
Key people | Staffan Schüberg (CEO), Albert Esteve (Chairman) |
Number of employees | 2,000 (average, 2023) |
Website | esteve.com |
Esteve is a Spanish international pharmaceutical company headquartered in Barcelona with more than 90 years of experience. Since its founding in 1929, Esteve has extended its pharmaceutical operations to Spain, Portugal, Germany, France, and the United Kingdom, Esteve supplies medicines to more than 7 million patients worldwide.
With industrial sites in Spain, Mexico, and China, Esteve covers the contract manufacturing (CMO) business. The company's product portfolio includes drugs for the treatment of serious diseases in therapeutic areas such as oncology and pain, the central nervous system, ophthalmology, neurology, and dermatology.
The company's origins date back to 1929, when Dr. Antoni Esteve i Subirana, researcher and entrepreneur, founded the firm. Now the family-owned company has around 2,000 employees and operates in different countries and continents, through subsidiary companies in Europe and the US and through production centers in Mexico and China, with products directly present in 40 countries and indirectly present, through licensing and distribution agreements, in over 60 countries around the world. [1]
Leadership Transition (2018): In 2018, Esteve Pharmaceuticals marked a significant shift in its leadership by appointing its first external CEO, signaling a new phase of professional management. This was a major change as the Esteve family had historically retained control of the company since its founding. [2]
Divestment and Acquisition (2020): In 2020, Esteve divested its entire generics business, Pensa, to Japanese pharmaceutical company Towa for an upfront payment of €320 million (approximately $357 million). This divestiture allowed Esteve to focus on more specialised medicines. [3] Additionally, Esteve acquired Riemser, a specialty pharmaceuticals company, from Ardian, expanding its portfolio in specialty medicine. [4]
Stake Sale to Lubea (2023): In 2023, Esteve sold a 26% stake of the company to Germany’s Lubea, valuing the entire firm at approximately €1.8 billion (around $1.98 billion). This sale highlighted the growing strategic partnerships Esteve was forming to further internationalize its operations. [5]
Acquisition of HRA Pharma Rare Diseases (2024): Esteve continued its expansion in the specialty and rare diseases sector by acquiring HRA Pharma Rare Diseases from Perrigo in 2024. The transaction, valued at up to €275 million ($296 million), included an upfront cash payment of €190 million ($205 million) and potential earnouts tied to future performance. The acquisition strengthens Esteve's portfolio with key drugs targeting conditions such as Cushing's syndrome and adrenocortical carcinoma, boosting their presence in Europe and the U.S. [6]
Expansion in Girona (2024): In 2024, Esteve Pharmaceuticals began the construction of a new manufacturing unit at its Girona plant to enhance its production of active pharmaceutical ingredients (APIs). This project, which is expected to be completed by 2026, involves a €100 million ($108 million) investment. The new facility will house both production and service buildings, allowing up to 150 cubic meters of reaction volume. Esteve anticipates a 45% increase in production capacity at this plant, with a further 15% growth in its overall global production capacity. [7]
Esteve focuses mainly on two health-related fields: the pharmaceutical field and the active pharmaceutical ingredient field, or fine chemistry. In the pharmaceutical field, Esteve has activities in research and development (R&D) of innovative medicines, particularly in pain and other areas with unmet therapeutic needs, based on both in-house and collaborative R&D programs as well as on innovative formulations. In 2017 for example, Esteve invested in the development of alternative treatments to strong opioids. [8] In the chemical field, the company focuses on the development of new processes, production and commercialization of active pharmaceutical ingredients.
Novartis AG is a Swiss multinational pharmaceutical corporation based in Basel, Switzerland. Consistently ranked in the global top five, Novartis is one of the largest pharmaceutical companies in the world and was the fourth largest by revenue in 2022.
The Takeda Pharmaceutical Company Limited is a Japanese multinational pharmaceutical company. It is the third largest pharmaceutical company in Asia, behind Sinopharm and Shanghai Pharmaceuticals, and one of the top 20 largest pharmaceutical companies in the world by revenue. The company has over 49,578 employees worldwide and achieved US$19.299 billion in revenue during the 2018 fiscal year. The company is focused on oncology, rare diseases, neuroscience, gastroenterology, plasma-derived therapies and vaccines. Its headquarters is located in Chuo-ku, Osaka, and it has an office in Nihonbashi, Chuo, Tokyo. In January 2012, Fortune Magazine ranked the Takeda Oncology Company as one of the 100 best companies to work for in the United States. As of 2015, Christophe Weber was appointed as the CEO and president of Takeda.
AstraZeneca plc (AZ) is a British-Swedish multinational pharmaceutical and biotechnology company with its headquarters at the Cambridge Biomedical Campus in Cambridge, England. It has a portfolio of products for major diseases in areas including oncology, cardiovascular, gastrointestinal, infection, neuroscience, respiratory, and inflammation. It was involved in developing the Oxford–AstraZeneca COVID-19 vaccine.
Shire plc was a UK-founded Jersey-registered specialty biopharmaceutical company. Originating in the United Kingdom with an operational base in the United States, its brands and products included Vyvanse, Lialda, and Adderall XR. Shire was acquired by Takeda Pharmaceutical Company on 8 January 2019.
UCB is a multinational biopharmaceutical company headquartered in Brussels, Belgium. UCB is an international company with revenue of €4.178 billion in 2016 which focuses primarily on research and development, specifically involving medications centered on epilepsy, Parkinson's disease, and Crohn's disease. The company's efforts are focused on treatments for severe diseases treated by specialists, particularly in the fields of central nervous system (CNS) disorders, inflammatory disorders, and oncology.
Perrigo Company plc is an American Irish-registered manufacturer of private label over-the-counter pharmaceuticals, and while 70% of Perrigo's net sales are from the U.S. healthcare system, Perrigo is legally headquartered in Ireland for tax purposes, which accounts for 0.60% of net sales. In 2013, Perrigo completed the sixth-largest US corporate tax inversion in history when it reregistered its tax status to Ireland to avoid U.S. corporate taxes. Perrigo maintains its corporate headquarters in Grand Rapids, Michigan, within Michigan State University's Grand Rapids Innovation Park.
Astellas Pharma Inc. is a Japanese multinational pharmaceutical company, formed on 1 April 2005 from the merger of Yamanouchi Pharmaceutical Co., Ltd. and Fujisawa Pharmaceutical Co., Ltd..
Teva Pharmaceutical Industries Ltd. is an Israeli multinational pharmaceutical company. Teva specializes primarily in generic drugs, but other business interests include branded-drugs, active pharmaceutical ingredients (APIs) and, to a lesser extent, contract manufacturing services and an out-licensing platform.
Actavis Generics is a global pharmaceutical company focused on acquiring, developing, manufacturing and marketing branded pharmaceuticals, generic and over-the-counter medicines, and biologic products. Actavis has a commercial presence across approximately 100 countries. The company has global headquarters in Dublin, Ireland and administrative headquarters in Parsippany-Troy Hills, New Jersey, United States.
Sun Pharmaceutical Industries Limited is an Indian multinational pharmaceutical company headquartered in Mumbai, that manufactures and sells pharmaceutical formulations and active pharmaceutical ingredients (APIs) in more than 100 countries across the globe. It is the largest pharmaceutical company in India and the fourth largest specialty generic pharmaceutical company in the world. The products cater to a vast range of therapeutic segments covering psychiatry, anti-infectives, neurology, cardiology, diabetology, gastroenterology, ophthalmology, nephrology, urology, dermatology, gynecology, respiratory, oncology, dental and nutritionals.
Leadiant Biosciences, formerly known as Sigma-Tau Industrie Farmaceutiche Riunite, was founded in 1957 by research chemist Claudio Cavazza.
Sumitomo Pharma Company Limited is a Japanese multinational pharmaceutical company. The company is focused on oncology, psychiatry, neurology, women's health issues, urological diseases among other areas. Its headquarters are located in Chuo-ku, Osaka.
Alexion Pharmaceuticals, Inc., a subsidiary of AstraZeneca, is a pharmaceutical company headquartered in Boston, Massachusetts that specializes in orphan drugs to treat rare diseases.
Aspen Pharmacare Holdings Limited is a public multinational pharmaceutical company headquartered in uMhlanga, South Africa. Founded in 1997, it listed on the Johannesburg Stock Exchange (JSE) in 1998, and purchased South African Druggists in 1999 before expanding into international markets. Currently the largest pharmaceutical company in Africa through aggressive mergers and expansion, with major manufacturing sites in locations such as Gqeberha in South Africa, Bad Oldesloe in Germany, Notre-Dame-de-Bondeville in France, and Oss, Netherlands, Aspen is known for manufacturing and distributing branded pharmaceuticals as well as generic HIV/AIDS antiretrovirals (ARVs) and cancer medications. Among other products, Aspen has also been involved in manufacturing the Janssen COVID-19 vaccine through "fill and finish", and has the rights to sell the product under its own brand name Aspenovax. The company's revenue in 2022 was R38.6 billion. In 2016 Aspen was fined for high prices on cancer drugs, and after an investigation Aspen committed to reduce prices for 5 years in the European Union.
Amneal Pharmaceuticals, Inc. is an American publicly traded generics and specialty pharmaceutical company. The company is headquartered in Bridgewater, New Jersey.
Jazz Pharmaceuticals plc is a global biopharmaceutical company with a focus on oncology and neuroscience. It was founded in 2003 in California, United States. One of the company's considerable products is the United States Food and Drug Administration (FDA) approved drug Xyrem, the sodium salt of the naturally occurring neurotransmitter γ-Hydroxybutyric acid (GHB). In 2017, net product sales of Xyrem were $1.187 billion, which represented 74% of the company's total net product sales. In 2019, Jazz was granted FDA-approval to market Sunosi with indications for treating excessive daytime sleepiness (EDS) in narcolepsy as well as obstructive sleep apnea (OSA). In 2022, it was announced that Axsome Therapeutics would be acquiring Sunosi from Jazz Pharmaceuticals.
Horizon Therapeutics plc was a biopharmaceutical company focused on researching, developing, and commercializing medicines that address critical needs for people impacted by rare and rheumatic diseases. Horizon primarily markets products in the United States, which represented 97% of Horizon's 2019 worldwide sales. Amgen acquired the company in October 2023.
Catalent, Inc. is a multinational corporation headquartered in Somerset, New Jersey. It is a global provider of delivery technologies, development, drug manufacturing, biologics, gene therapies and consumer health products. It employs more than 14,000 people, including approximately 2,400 scientists and technicians. In fiscal year 2020, it generated over $3 billion in annual revenue.
CSL Vifor is a global specialty pharmaceuticals company in the treatment areas of iron deficiency, dialysis, nephrology & rare disease. It is headquartered in Switzerland and consists of CSL Vifor, Vifor Fresenius Medical Care Renal Pharma (VFMCRP) and Sanifit Therapeutics.
Viatris Inc. is an American global pharmaceutical and healthcare corporation headquartered in Canonsburg, Pennsylvania. The corporation was formed through the merger of Mylan and Upjohn, a legacy division of Pfizer, on November 16, 2020.